Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 101.80K | 41.70K | 38.40K | 102.60K | 41.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.80K | 41.70K | 38.40K | 102.60K | 41.40K |
| Cost of Revenue | 6.60K | -- | -108.90K | 2.90K | -- |
| Gross Profit | 95.10K | 41.70K | 147.30K | 99.70K | 41.40K |
| SG&A Expenses | 555.90K | 303.80K | 240.20K | 378.10K | 155.40K |
| Depreciation & Amortization | 20.30K | 21.50K | 16.70K | 11.60K | 11.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 645.30K | 349.50K | 181.20K | 397.10K | 191.10K |
| Operating Income | -543.60K | -307.80K | -142.80K | -294.40K | -149.70K |
| Income Before Tax | -566.50K | -348.30K | -163.80K | -303.20K | -165.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -566.50K | -348.30K | -163.80K | -303.20K | -165.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -566.50K | -348.30K | -163.80K | -303.20K | -165.70K |
| EBIT | -543.60K | -307.80K | -142.80K | -294.40K | -149.70K |
| EBITDA | -534.40K | -298.00K | -139.30K | -294.10K | -138.00K |
| EPS Basic | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 101.76M | 88.57M | 91.76M | 89.15M | 86.91M |
| Average Diluted Shares Outstanding | 101.76M | 88.57M | 91.76M | 89.15M | 86.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |